A patient with a feminizing malignant Leydig cell tumor is presented. Hormonal assays revealed increased production of prolactin, estradial. and total estrogens. Eleven years after the onset of his disease he remains clinically well.
Treatment of malignant leydig cell tumor
β Scribed by Kenneth A. Bertram; Brian Bratloff; George F. Hodges; Howard Davidson
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 794 KB
- Volume
- 68
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Malignant Leydig cell tumors (LCT) are rare. Only 32 cases of malignant LCT (as evidenced by metastatic spread) were reported. Generally metastatic spread occurs within 2 years of the primary LCT, and the patient dies within 2 years of the discovery of metastatic disease. The tumor is highly resistant to both radiation and chemotherapy. It also has a great propensity for recurring after surgical resection. A case is reported of a patient whose metastatic disease occurred 8 years after his primary LCT had been resected. He was treated with doxorubicin and mitotane without response. The clinical features of this case are highlighted, and a review of the literature describing treatment of this rare disease is presented.
π SIMILAR VOLUMES
A 51-year-old man had a malignant Leydig cell tumor of the testis with elevation of serum estrone and endrostenedione as well as urine chorionic gonadotropin. The fine structural features of the neoplasm resembled those of nontumorous Leydig cells as well as cells of Leydig cell adenomas, except for
Dear Dr. Bedrossian: Leydig (interstitial) cell tumors are rare neoplasms accounting for 1-3% of all testicular tumors. Only 10% of these neoplasms will demonstrate malignant behavior, characterized by metastases to retroperitoneal lymph nodes, lung, and liver. While rare primary Leydig cell tumors